Pharmacokinetics of Metoprolol in Patients with Hepatic Cirrhosis

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1981 Sep 1

PMID 7333059

Citations 30

Authors

C G Regardh

L Jordo

M ERVIK

P Lundborg

R Olsson

O Ronn

Affiliations

Soon will be listed here.

Abstract

The selective beta 1-adrenoceptor antagonist metoprolol is eliminated primarily by hepatic metabolism and usually less than 5% of an oral dose is excreted unchanged in the urine. The effects of impaired liver function on the pharmacokinetics of metoprolol were studied in 10 patients with hepatic cirrhosis. All subjects were given single doses of 20mg intravenously and 50mg orally on separate days. The mean fraction of the drug available systematically was 84 +/- 10% in patients and 50 +/- 11% in a control group of 6 healthy subjects (p less than 0.05). The total body clearance of metoprolol in the cirrhotics was 0.61 +/- 0.13L/min and in the controls 0.80 +/- 0.11L/min. These values correspond to elimination half-lives of 7.2 +/- 1.2 and 4.2 +/- 1.1 hours, respectively. The differences were not statistically significant. Impaired liver function had no effect on the volume of distribution of metoprolol. Total clearance was weakly but linearly related to galactose clearance (r2 = 0.52; p less than 0.05), and the half-life was related to serum bilirubin (r2 = 0.74; p less than 0.01).

Citing Articles

Physiologically Based Pharmacokinetic Model To Predict Metoprolol Disposition in Healthy and Disease Populations.

Zamir A, Rasool M, Imran I, Saeed H, Khalid S, Majeed A ACS Omega. 2023; 8(32):29302-29313.

PMID: 37599939 PMC: 10433471. DOI: 10.1021/acsomega.3c02673.

Clinical Pharmacokinetics of Metoprolol: A Systematic Review.

Zamir A, Hussain I, Ur Rehman A, Ashraf W, Imran I, Saeed H Clin Pharmacokinet. 2022; 61(8):1095-1114.

PMID: 35764772 DOI: 10.1007/s40262-022-01145-y.

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.

Lee C, Kang P, Cho C, Park H, Lee Y, Bae J Arch Pharm Res. 2022; 45(6):433-445.

PMID: 35763157 DOI: 10.1007/s12272-022-01394-2.

Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.

Duthaler U, Bachmann F, Suenderhauf C, Grandinetti T, Pfefferkorn F, Haschke M Clin Pharmacokinet. 2022; 61(7):1039-1055.

PMID: 35570253 PMC: 9287224. DOI: 10.1007/s40262-022-01119-0.

Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Bouchard J, Shepherd G, Hoffman R, Gosselin S, Roberts D, Li Y Crit Care. 2021; 25(1):201.

PMID: 34112223 PMC: 8194226. DOI: 10.1186/s13054-021-03585-7.

References

Pentikainen P, Neuvonen P, Jostell K . Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol. 1980; 17(4):275-84. DOI: 10.1007/BF00625801. View

Hoffmann K, Regardh C, Aurell M, ERVIK M, Jordo L . The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet. 1980; 5(2):181-91. DOI: 10.2165/00003088-198005020-00005. View

Wilkinson G, Schenker S . Drug disposition and liver disease. Drug Metab Rev. 1975; 4(2):139-75. DOI: 10.3109/03602537508993754. View

Jordo L, Attman P, Aurell M, Johansson L, Johnsson G, Regardh C . Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980; 5(2):169-80. DOI: 10.2165/00003088-198005020-00004. View

Wood A, Kornhauser D, Wilkinson G, SHAND D, Branch R . The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet. 1978; 3(6):478-87. DOI: 10.2165/00003088-197803060-00005. View

ERVIK M, Hoffmann K . Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards. Biomed Mass Spectrom. 1981; 8(7):322-6. DOI: 10.1002/bms.1200080708. View

Neal E, Meffin P, GREGORY P, Blaschke T . Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology. 1979; 77(1):96-102. View

Huffman D, Shoeman D, Pentikainen P, AZARNOFF D . The effect of spironolactone on antipyrine metabolism in man. Pharmacology. 1973; 10(6):338-44. DOI: 10.1159/000136455. View

Taylor S, Rawlins M, Smith S . Spironolactone--a weak enzyme inducer in man. J Pharm Pharmacol. 1972; 24(7):578-9. DOI: 10.1111/j.2042-7158.1972.tb09061.x. View

10.

Johnsson G, Regardh C, SOLVELL L . Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh). 1975; 36(Suppl 5):31-44. DOI: 10.1111/j.1600-0773.1975.tb03320.x. View

11.

Jordo L, Johnsson G, Lundborg P, Persson B, Regardh C, Ronn O . Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide. Br J Clin Pharmacol. 1979; 7(6):563-7. PMC: 1429665. DOI: 10.1111/j.1365-2125.1979.tb04643.x. View

12.

Homeida M, Jackson L, Roberts C . Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J. 1978; 2(6144):1048-50. PMC: 1608159. DOI: 10.1136/bmj.2.6144.1048. View

13.

Borg K, Carlsson E, Hoffmann K, Jonsson T, THORIN H, Wallin B . Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol (Copenh). 1975; 36(Suppl 5):125-35. DOI: 10.1111/j.1600-0773.1975.tb03329.x. View

14.

Ochs H, Greenblatt D, BODEM G, Smith T . Spironolactone. Am Heart J. 1978; 96(3):389-400. DOI: 10.1016/0002-8703(78)90052-2. View

15.

Kendall M, Brown D, YATES R . Plasma metoprolol concentrations in young, old and hypertensive subjects. Br J Clin Pharmacol. 1977; 4(4):497-9. PMC: 1429045. View

16.

Ohnhaus E, Munch U, Meier J . [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases]. Schweiz Med Wochenschr. 1976; 106(49):1748-50. View

17.

Regardh C, Ek L, Hoffmann K . Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol--metabolite of metoprolol--in the dog. J Pharmacokinet Biopharm. 1979; 7(5):471-9. DOI: 10.1007/BF01062389. View

18.

Branch R, James J, Read A . A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol. 1976; 3(2):243-9. PMC: 1428884. DOI: 10.1111/j.1365-2125.1976.tb00599.x. View

19.

Myers M, Thiessen J . Metoprolol kinetics and dose response in hypertensive patients. Clin Pharmacol Ther. 1980; 27(6):756-62. DOI: 10.1038/clpt.1980.106. View

20.

Bengtsson C, Johnsson G, Regardh C . Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther. 1975; 17(4):400-8. DOI: 10.1002/cpt1975174400. View